Screener
iRadimed IRMD Total Liabilities & Equity
Total Liabilities & Equity at other companies
Other financials
Where this comes from
Reported directly by iRadimed in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.
The source filing: iRadimed’s 10-Q, filed May 1, 2026.
- Filed
- May 1, 2026, 4:08 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-029325
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Deferred revenue, non-current | 3,757 | 3,978 |
| Total liabilities | $15,875 | 14,158 |
| Stockholders’ equity: | ||
| Common stock; $0.0001 par value per share; 31,500,000 shares authorized; 12,782,837 shares issued and outstanding as of March 31, 2026, and 12,781,774 shares issued and outstanding as of December 31, 2025 | $1 | $1 |
| Additional paid-in capital | 31,020 | 30,386 |
| Retained earnings | 67,493 | 64,231 |
| Total stockholders' equity | 98,514 | 94,618 |
| Total liabilities and stockholders’ equity | $114,389 | $108,776 |
Item 1. Condensed Financial Statements
FAQ
- What is iRadimed's total liabilities & equity?
- iRadimed (IRMD) reported total liabilities & equity of $114.39M in Q1 2026.
- How has iRadimed's total liabilities & equity changed year-over-year?
- iRadimed's total liabilities & equity increased by 12.4% year-over-year, from $101.73M to $114.39M.
- What is the long-term trend for iRadimed's total liabilities & equity?
- Over 5 years (2020 to 2025), iRadimed's total liabilities & equity has grown at a 8.9% compound annual growth rate (CAGR), from $71.07M to $108.78M.
- What does total liabilities & equity mean?
- Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.
Ask your AI about iRadimed's total liabilities & equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude